Tagrisso 80 — Osimertinib 80 mg (30 Tablets)

Tagrisso (Osimertinib) is prescribed by oncologists for the following indications:

• 🔹 Adjuvant Therapy: After radical surgery in patients with NSCLC harboring EGFR mutations (exon 19 deletion or L858R substitution).
• 🔹 First-Line Therapy: Treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations.
• 🔹 Second-Line Therapy: Treatment of metastatic NSCLC with a positive T790M mutation after progression on therapy with other EGFR inhibitors.

Sales Form: 1 pack contains 30 tablets of 80 mg.

⚠️ INSTRUCTIONS FOR USE:

• Dosage Regimen: The standard dosage is 80 mg (1 tablet) once daily.
• Method: The tablet should be swallowed whole with water. It can be taken with or without food at the same time each day.
• Special Features: If the patient has difficulty swallowing the tablet whole, it can be dispersed in 50 ml of non-carbonated water (no other liquids should be used), stirred thoroughly, and consumed immediately.
• Duration: Treatment continues until disease progression or the occurrence of severe side effects.
• Storage: Store in the original packaging at temperatures up to 30°C.

• ⛔ Hypersensitivity: Hypersensitivity to osimertinib.
• ⛔ Pregnancy and Family Planning: The drug is contraindicated in pregnant women due to risk to the fetus. Women must use reliable contraception during therapy and for 2 months after; men should use it for 4 months.
• ⛔ Lactation: Breastfeeding is prohibited during the treatment period.
• ⛔ Interactions: Concomitant use with St. John's wort preparations is strictly not recommended.
• ⛔ Pediatric Use: Safety for patients under 18 years of age has not been established.

Tagrisso is generally well-tolerated; however, the following side effects may occur:

• 🧪 Skin Reactions: Dry skin, rash, itching, inflammation around the nails (paronychia).
• 🤢 GI Tract: Diarrhea (most common), stomatitis (mouth sores), decreased appetite.
• 🩸 Blood: Decreased levels of white blood cells, platelets, or red blood cells.
• 🫁 Lungs: In rare cases — interstitial lung disease (ILD). If sudden cough or shortness of breath appears, seek medical attention immediately.
• ❤️ Heart: QT interval prolongation (ECG monitoring required for patients at risk).
• ⚠️ Important: If signs of heart failure or acute lung inflammation appear, therapy should be suspended.